Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Global Report 2026

The next-generation adeno-associated virus (AAV) gene therapy delivery market size has grown rapidly in recent years. It will grow from $4.96 billion in 2025 to $5.93 billion in 2026 at a compound annual growth rate (CAGR) of 19.5%. The growth during the historic period can be attributed to increasing gene therapy research activities, rising prevalence of rare genetic disorders, growing investment in biotechnology innovation, expanding clinical trials for AAV-based therapies, and increasing demand for targeted therapeutic approaches.

The next-generation adeno-associated virus (AAV) gene therapy delivery market size is expected to see rapid growth in the next few years. It will grow to $11.91 billion in 2030 at a compound annual growth rate (CAGR) of 19.1%. The growth in the forecast period can be attributed to increasing adoption of personalized gene therapies, rising development of advanced AAV vector engineering platforms, growing commercialization of gene therapy products, expanding research in precision medicine applications, and increasing demand for safer and more effective genetic treatments. Major trends in the forecast period include growing adoption of engineered AAV capsid technologies for targeted gene delivery, increasing development of immune response reduction strategies in AAV therapies, rising demand for durable and precise gene expression platforms, expanding applications of next-generation AAV vectors in rare disease treatments, and increasing focus on scalable manufacturing processes for advanced gene therapy vectors.

The increasing adoption of targeted gene therapies is expected to drive the growth of the next-generation adeno-associated virus gene therapy delivery market going forward. Targeted gene therapies refer to treatments that deliver genetic material to specific cells or tissues in the body to correct or modify disease-causing genes while reducing effects on non-target cells. The increasing adoption of targeted gene therapies is driven by advancements in gene delivery technologies that enhance precision, safety, and efficiency in delivering therapeutic genes directly to specific cells or tissues. The growing adoption of targeted gene therapies increases the demand for more accurate, efficient, and tissue-specific delivery systems, thereby accelerating the development and improvement of next-generation adeno-associated virus (AAV) gene therapy delivery platforms. For instance, in January 2024, according to the American Society of Gene & Cell Therapy, a US-based organization focused on gene and cell therapy, the number of gene therapies in Phase III increased by 10% in the fourth quarter of 2023 compared with the previous quarter, marking the first growth since the third quarter of 2022. Therefore, the increasing adoption of targeted gene therapies is contributing to the growth of the next-generation adeno-associated virus gene therapy delivery market.

Major companies operating in the next-generation adeno-associated virus gene therapy delivery market are focusing on developing innovative solutions, such as engineered capsids, to improve gene delivery efficiency, reduce dosage requirements, and enhance overall safety and therapeutic outcomes. Engineered capsids are genetically modified protein shells of adeno-associated viruses (AAVs) developed to enhance gene delivery by improving tissue targeting, increasing transduction efficiency, and minimizing immune system recognition. For instance, in May 2026, Affinia Therapeutics, a US-based biotechnology company, presented new preclinical and translational data at a leading gene and cell therapy conference, showcasing advancements in its AAV gene therapy platform. The update highlighted progress in capsid engineering, scalable manufacturing processes, and clinical development strategies aimed at improving targeted gene delivery performance. Its lead candidate, AFTX-201, was highlighted for its potential in treating BAG3-associated dilated cardiomyopathy through improved cardiac-specific gene expression enabled by its proprietary AAV vector technology.

In January 2024, Novartis AG, a Switzerland-based multinational pharmaceutical company focused on innovative medicines and advanced gene therapies, expanded its collaboration with Voyager Therapeutics through a deal valued at up to $1.2 billion to develop next-generation gene therapies for neurological diseases. Under this collaboration, Novartis aims to utilize Voyager’s proprietary TRACER adeno-associated virus (AAV) capsid platform to enhance central nervous system (CNS) targeting, improve blood-brain barrier penetration, and enable more effective gene delivery for conditions such as Huntington’s disease and spinal muscular atrophy. Voyager Therapeutics Inc. is a US-based biotechnology company specializing in engineered AAV capsids and gene therapy delivery technologies focused on neurological disorders.

Major companies operating in the next-generation adeno-associated virus (aav) gene therapy delivery market are Pfizer Inc., Novartis AG, Bayer AG, Astellas Pharma Inc., Sarepta Therapeutics Inc., Adverum Biotechnologies Inc., uniQure N.V., REGENXBIO Inc., Rocket Pharmaceuticals Inc., MeiraGTx Holdings plc, 4D Molecular Therapeutics, Voyager Therapeutics Inc., Taysha Gene Therapies Inc., Passage Bio Inc., Solid Biosciences Inc., Affinia Therapeutics Inc., Encoded Therapeutics Inc., Capsida Biotherapeutics Inc, AAVantgarde Bio S.r.l., VectorY Therapeutics B.V., Ring Therapeutics, Dyno Therapeutics Inc., Généthon, Sangamo Therapeutics Inc.

North America was the dominating region in the next-generation adeno-associated virus (AAV) gene therapy delivery market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the next-generation adeno-associated virus (AAV) gene therapy delivery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the next-generation adeno-associated virus (AAV) gene therapy delivery market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.